Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review

GlobalData
68 Pages - GLDATA62444
$125.00

Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza (azacitidine) for the treatment of myelodysplastic syndromes (MDS); Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancer; Otezla (apremilast) for psoriatic arthritis; and Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL) and eripheral T-cell lymphoma (PTCL). The company also has several products in various stages of development for the treatment of hematological and solid tumor cancers. It has manufacturing facilities in Boudry and Zofingen in Switzerland; and Arizona, the US. Celgene is headquartered in Summit, New Jersey, the US.

Celgene Corp Key Recent Developments

Feb 23, 2017: Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer
Jan 26, 2017: Celgene Reports Fourth Quarter and Full-Year 2016 Operating and Financial Results
Jan 12, 2017: Celgene Increases Adoption of Medidata Clinical Cloud, Gaining Further Value from Implementation of Medidata's Strategic Monitoring and Data Analytics Solutions
Jan 09, 2017: Celgene Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance
Dec 03, 2016: Celgene, Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Celgene Corp - Key Facts 6
Celgene Corp - Key Employees 7
Celgene Corp - Key Employee Biographies 8
Celgene Corp - Major Products and Services 9
Celgene Corp - Pharmaceutical Pipeline Products Data 11
Celgene Corp, Pipeline Products by Therapy Area 11
Celgene Corp, Pipeline Products by Development Phase 12
Celgene Corp - History 13
Celgene Corp - Company Statement 21
Celgene Corp - Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Section 2 – Company Analysis 29
Celgene Corp - Business Description 29
Celgene Corp - Corporate Strategy 31
Celgene Corp - SWOT Analysis 32
SWOT Analysis - Overview 32
Celgene Corp - Strengths 32
Celgene Corp - Weaknesses 33
Celgene Corp - Opportunities 34
Celgene Corp - Threats 35
Celgene Corp - Key Competitors 36
Section 3 – Company Financial Ratios 37
Financial Ratios - Capital Market Ratios 37
Financial Ratios - Annual Ratios 38
Performance Chart 40
Financial Performance 40
Financial Ratios - Interim Ratios 41
Financial Ratios - Ratio Charts 42
Section 4 – Company’s Lifesciences Financial Deals and Alliances 43
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 43
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 44
Celgene Corp, Recent Deals Summary 45
Section 5 – Company’s Recent Developments 46
Feb 23, 2017: Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer 46
Jan 26, 2017: Celgene Reports Fourth Quarter and Full-Year 2016 Operating and Financial Results 47
Jan 12, 2017: Celgene Increases Adoption of Medidata Clinical Cloud, Gaining Further Value from Implementation of Medidata's Strategic Monitoring and Data Analytics Solutions 50
Jan 09, 2017: Celgene Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance 51
Dec 03, 2016: Celgene, Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project 53
Nov 22, 2016: Nearly 350 Abstracts Evaluating Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting 54
Nov 01, 2016: Celgene and IBM Watson Health Forge Collaboration Designed to Transform Patient Safety Monitoring 57
Oct 27, 2016: Celgene Reports Third Quarter 2016 Operating and Financial Results 58
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 61
Oct 18, 2016: Celgene and Sage Bionetworks Announce Technology Collaboration to Develop Observational Study Using the Apple ResearchKit Framework 63
Section 6 – Appendix 64
Methodology 64
Ratio Definitions 64
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
Celgene Corp, Key Facts 6
Celgene Corp, Key Employees 7
Celgene Corp, Key Employee Biographies 8
Celgene Corp, Major Products and Services 9
Celgene Corp, Number of Pipeline Products by Therapy Area 11
Celgene Corp, Number of Pipeline Products by Development Stage 12
Celgene Corp, History 13
Celgene Corp, Other Locations 24
Celgene Corp, Subsidiaries 24
Celgene Corp, Key Competitors 36
Celgene Corp, Ratios based on current share price 37
Celgene Corp, Annual Ratios 38
Celgene Corp (Cont...1), Annual Ratios 39
Celgene Corp, Interim Ratios 41
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 43
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 44
Celgene Corp, Recent Deals Summary 45
Currency Codes 64
Capital Market Ratios 64
Equity Ratios 65
Profitability Ratios 65
Cost Ratios 66
Liquidity Ratios 66
Leverage Ratios 66
Efficiency Ratios 67

List of Figures
Celgene Corp, Pipeline Products by Therapy Area 11
Celgene Corp, Pipeline Products by Development Phase 12
Celgene Corp, Performance Chart (2012 - 2016) 40
Celgene Corp, Ratio Charts 42
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 43
Celgene Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 44

$125.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838